Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $3.4 million.

  • Mimedx's Other Working Capital Changes rose 40632.24% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 864311.93%. This contributed to the annual value of $1.1 million for FY2024, which is 17244.3% up from last year.
  • Mimedx's Other Working Capital Changes amounted to $3.4 million in Q3 2025, which was up 40632.24% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Other Working Capital Changes peaked at $3.8 million during Q4 2024, and registered a low of -$6.5 million during Q4 2021.
  • Its 5-year average for Other Working Capital Changes is -$175421.1, with a median of -$729000.0 in 2023.
  • Per our database at Business Quant, Mimedx's Other Working Capital Changes crashed by 53829.79% in 2023 and then surged by 40632.24% in 2025.
  • Over the past 5 years, Mimedx's Other Working Capital Changes (Quarter) stood at -$6.5 million in 2021, then soared by 143.97% to $2.8 million in 2022, then dropped by 0.42% to $2.8 million in 2023, then soared by 35.49% to $3.8 million in 2024, then dropped by 10.16% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $1.6 million for Q2 2025, and $699000.0 during Q1 2025.